Literature DB >> 17948029

The 'kiss of death' by dendritic cells to cancer cells.

C W Chan1, F Housseau.   

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) specialized in the stimulation of naïve T lymphocytes, which are key components of antiviral and antitumor immunity. DCs are 'sentinels' of the immune system endowed with the mission to (1) sense invading pathogens as well as any form of tissue distress and (2) alert the effectors of the immune response. They represent a very heterogeneous population including subsets characterized by their anatomical locations and specific missions. Beyond their unique APC features, DCs exhibit a large array of effector functions that play critical roles in the induction and regulation of the cell-mediated as well as humoral immune responses. In the course of the antitumor immune response, DCs are unique in engulfing tumor cells killed by natural killer (NK) cells and cross-presenting tumor-associated antigens to cytotoxic T lymphocytes (CTLs). However, while DCs mediate antitumor immune responses by stimulating tumor-specific CTLs and NK cells, direct tumoricidal mechanisms have been recently evoked. This review addresses the other face of DCs to directly deliver apoptotic signals to stressed cells, their role in tumor cell death, and its implication in the design of DC-based cancer immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17948029     DOI: 10.1038/sj.cdd.4402235

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  24 in total

1.  Cellular senescence, ageing and disease.

Authors:  D G A Burton
Journal:  Age (Dordr)       Date:  2008-09-04

2.  Peptidoglycan-treated tumor antigen-pulsed dendritic cells impart complete resistance against tumor rechallenge.

Authors:  A Patidar; S Selvaraj; P Chauhan; C A Guzman; T Ebensen; A Sarkar; D Chattopadhyay; B Saha
Journal:  Clin Exp Immunol       Date:  2020-06-26       Impact factor: 4.330

3.  Pseudomonas aeruginosa preparation plus chemotherapy for advanced non-small-cell lung cancer: a randomized, multicenter, double-blind phase III study.

Authors:  Jianhua Chang; Yunpeng Liu; Baohui Han; Caicun Zhou; Chunxue Bai; Jin Li
Journal:  Med Oncol       Date:  2015-03-24       Impact factor: 3.064

Review 4.  Innate immune cells in breast cancer--from villains to heroes?

Authors:  Tim Kees; Mikala Egeblad
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-07-26       Impact factor: 2.673

5.  PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.

Authors:  Neale T Hanke; Collin J LaCasse; Claire B Larmonier; Darya Alizadeh; Malika Trad; Nona Janikashvili; Bernard Bonnotte; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Eur J Immunol       Date:  2014-05-23       Impact factor: 5.532

6.  IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity.

Authors:  Maria Pletneva; Hongni Fan; Jang-June Park; Vedran Radojcic; Chunfa Jie; Yanxing Yu; Camie Chan; Alec Redwood; Drew Pardoll; Franck Housseau
Journal:  Cancer Res       Date:  2009-08-15       Impact factor: 12.701

Review 7.  Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.

Authors:  Neale Hanke; Darya Alizadeh; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 8.  IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.

Authors:  Ramesh B Batchu; Oksana V Gruzdyn; Bala K Kolli; Rajesh Dachepalli; Prem S Umar; Sameer K Rai; Namrata Singh; Pavan S Tavva; Donald W Weaver; Scott A Gruber
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Granule exocytosis mediates immune surveillance of senescent cells.

Authors:  A Sagiv; A Biran; M Yon; J Simon; S W Lowe; V Krizhanovsky
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

10.  Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.

Authors:  Sébastien Anguille; Eva Lion; Jurjen Tel; I Jolanda M de Vries; Karen Couderé; Phillip D Fromm; Viggo F Van Tendeloo; Evelien L Smits; Zwi N Berneman
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.